

## Special Issue

# Molecular Mechanisms and Treatment of Rheumatic Diseases

### Message from the Guest Editors

It gives us great pleasure and excitement to announce the opening of the submission of articles for the Special Issue "Molecular Mechanisms and Treatment of Rheumatic Diseases". Since the beginning of the 2000s, we have been witnessing a revolution in the therapeutic approach to rheumatological diseases both in terms of the standardization of the treatment with the appearance and regular updating of treatment guidelines, as well as the monitoring modality and the established therapeutic targets. However, despite the absolute advance of knowledge, there are still many gray areas and unfulfilled needs. Our goal is to stimulate research and clinical interest in this field, which, due to its complexity, lends itself so much to a multidisciplinary approach. We welcome the submission of original research and review articles on the following topics:

- Diagnostic tools;
- Clinical and immunological correlations;
- Therapeutic challenges;
- Risk stratification;
- Achieving goals in management and treatment;
- Old and new therapeutic targets;
- Comorbidities (diagnosis, correlations, and management).

---

### Guest Editors

Prof. Dr. Ruxandra Ionescu

Department of Internal Medicine and Rheumatology, Universitatea de Medicina si Farmacie Carol Davila din Bucuresti, Bucharest, Romania

Dr. Daniela Opris-Belinski

Department of Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania

---

### Deadline for manuscript submissions

30 September 2025



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/195607](https://mdpi.com/si/195607)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).